GH Research (GHRS) Enterprise Value (2021 - 2026)
GH Research (GHRS) posted quarterly Enterprise Value of -$246.3 million for Q4 2025, down 104.91% year-over-year from $5.0 billion in Q4 2024, and up 1.36% quarter-over-quarter from -$249.7 million in Q3 2025.
Analysis
GH Research (GHRS) Enterprise Value (2021 - 2026) Analysis & Trends
GH Research's Enterprise Value history runs 6 years deep, the most recent figure standing at -$246.3 million for Q4 2025.
- In Q4 2025, Enterprise Value fell 104.91% year-over-year to -$246.3 million; the TTM figure through Dec 2025 stood at -$246.3 million (down 104.91% YoY), while the FY2025 annual figure was -$246.3 million, down 104.91% from the prior year.
- Enterprise Value for Q4 2025 stood at -$246.3 million, up from -$249.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$120.2 million in Q4 2024, with the low at -$280.7 million in Q3 2021.
- The 5-year median for Enterprise Value is -$206.1 million (2022), against an average of -$200.6 million.
- The sharpest annual moves came in 2021 and 2023: Enterprise Value sank 5535620.0% in 2021, then surged 44.76% in 2023.
- GH Research's Enterprise Value stood at -$276.8 million in 2021, then jumped by 40.04% to -$166.0 million in 2022, then increased by 19.23% to -$134.0 million in 2023, then increased by 10.34% to -$120.2 million in 2024, then tumbled by 104.91% to -$246.3 million in 2025.
- Business Quant data shows GHRS's Enterprise Value at -$246.3 million in Q4 2025, -$249.7 million in Q3 2025, and -$253.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | GH Research | 1.70 Bn | 1.34 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | 604.81 Mn |
| Dec 31, 2025 | 507.07 Mn |
| Sep 30, 2025 | 494.35 Mn |
| Jun 30, 2025 | 380.35 Mn |
| Mar 31, 2025 | 316.36 Mn |
| Dec 31, 2024 | 244.02 Mn |
| Sep 30, 2024 | 225.49 Mn |
| Jun 30, 2024 | 477.55 Mn |
| Mar 31, 2024 | 425.79 Mn |
| Dec 31, 2023 | 277.34 Mn |
| Sep 30, 2023 | 380.88 Mn |
| Jun 30, 2023 | 465.60 Mn |
| Mar 31, 2023 | 256.51 Mn |
| Dec 31, 2022 | 339.69 Mn |
| Sep 30, 2022 | 347.54 Mn |
| Jun 30, 2022 | 253.79 Mn |
| Mar 31, 2022 | 680.71 Mn |
| Dec 31, 2021 | 936.87 Mn |
| Sep 30, 2021 | 344.86 Mn |